

## 17 $\beta$ -estradiol and progesterone upregulate cyclooxygenase-2 expression in the human gingival fibroblasts

<sup>1</sup>Ostad S. N., <sup>2</sup>Motahhary P., <sup>2</sup>Beshkar M., <sup>\*1</sup>Ghahremani M.H.

<sup>1</sup>Department of Toxicology and Pharmacology, Faculty of Pharmacy, <sup>2</sup>Department of Oral and Maxillofacial Pathology, Faculty of Dentistry, Tehran University of Medical Sciences, Tehran, Iran

Received 2 Jan 2006 ; Revised 22 April 2006; Accepted 7 May 2006

### ABSTRACT

Gingivitis is associated with 60-75% of all pregnancies and elevated levels of 17 $\beta$ -estradiol and progesterone is known to increase gingival inflammation and the proinflammatory prostaglandins in the human gingiva. Since cyclooxygenase-2 (COX-2) is an inducible enzyme responsible for the production of prostaglandins at the sites of inflammation, it is plausible to hypothesize that 17 $\beta$ - estradiol and progesterone could contribute to gingival inflammation by upregulation of COX-2 expression and subsequent prostaglandin formation. To examine this hypothesis, primary cultures of human gingival fibroblasts (HGFs) from either sex were established. The cells were treated with different concentrations ( $10^{-5}$ ,  $10^{-7}$ , and  $10^{-9}$  M) of 17 $\beta$ -estradiol and progesterone, and expression of COX-2 protein was detected immunocytochemically. The growth potential and proliferation of these cells were studied using trypan blue exclusion method and MTT assay. The results show that both 17 $\beta$ -estradiol and progesterone upregulate COX-2 expression in the HGFs significantly. In addition, progesterone is more effective than 17 $\beta$ -estradiol to induce COX-2 expression at  $10^{-5}$ M but not at lower concentration ( $10^{-9}$ M). Furthermore, cells prepared from either sex do not show any difference in COX-2 expression following hormone treatment and neither hormones show any changes in proliferation of these cells. In conclusion, the results of this investigation clearly illustrate significant regulatory effects of 17 $\beta$ -estradiol and progesterone on COX-2 expression in the cultured HGFs. Thus, one possible pathogenetic mechanism of the female sex hormone-associated gingivitis *in vivo* may be the synthesis of proinflammatory prostaglandins via upregulation of COX-2 expression by gingiva in response to elevated levels of circulating estrogens and progesterone.

**Keywords:** Gingivitis, Sex hormone, COX-2, Prostaglandin, Immunocytochemistry.

### INTRODUCTION

Gingival inflammation is the most common oral manifestation of elevated levels of circulating estrogens and progesterone in conditions such as pregnancy and oral contraceptive usage (1-3). There are several lines of evidences elucidating various aspects of the relationship between these hormones and gingival inflammation (4, 5). Gingival inflammation has been characterized by an increase in formation of prostaglandins (PGs) within the gingival tissue (6). It has been reported that sex hormones increase PG synthesis in various cells (7-9). In endothelial cell, progesterone has upregulates PG production and expression of COX enzyme (7). Furthermore, in cultured human uterine myometrial cells, 17 $\beta$ -estradiol up-regulates prostacyclin production via an increase in expression of both COX-1 and COX-2(10). In this regard, data from *in vitro*

investigations suggested that increase of PG in the human gingival tissue is mediated by the upregulation of cyclooxygenase-2 (COX-2) isoenzyme in the gingival fibroblasts and subsequent PG formation (11). On the other hand, PG synthesis has been shown to be stimulated by 17 $\beta$ -estradiol and progesterone in the human gingival tissue homogenate (12). However, it is unclear whether COX-2 is upregulated in the human gingival fibroblasts stimulated by estradiol and progesterone.

These evidences converge to formulate a hypothesis by which 17 $\beta$ -estradiol and progesterone give rise to gingival inflammation. Therefore, we have investigated the effect of 17 $\beta$ -estradiol and progesterone on human primary gingival fibroblasts and evaluated the expression of COX-2. Stimulaton of the human gingival fibroblasts (HGFs) with estradiol and progesterone may give

Corresponding: mhghahremani@tums.ac.ir

rise to upregulation of COX-2 expression and subsequent prostaglandin production and gingival inflammation.

## MATERIALS AND METHODS

### *Chemicals and Materials*

All cell culture materials were obtained from PAN Biotech (Aidenbach, Germany); FBS was purchased from Gibco (Paisley, UK) and all culture dishes were obtained from NUNC (Roskilde, Denmark). Amphotericin B, hematoxylin, MTT, bovine serum albumin, progesterone and 17 $\beta$ -estradiol were purchased from Sigma-Aldrich (Steinheim, Germany). Rabbit polyclonal anti COX-2 antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, USA) and immunocytochemical detection was performed using biotin-streptavidin-conjugated ABC kit from Dako Cytomation (Glostrup, Denmark).

### *Fibroblast cultures*

Primary cultures of human gingival fibroblasts (HGFs) were established from gingival biopsies obtained from six healthy individuals (three males and three females), age of 19-26 years with no clinical signs of periodontal disease. All biopsies were obtained from retromolar gingival tissue during surgical extraction of impacted third molars. Informed consent was obtained from all donors prior to the surgical procedure. HGFs were obtained from tissue explants using a slight modification of a previously established protocol (13). Briefly, explants were rinsed in phosphate buffered solution (PBS) and finely chopped into pieces of about 1-2 mm<sup>3</sup>. Tissues were then placed in 6-well plates and carefully layered with Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, and 1  $\mu$ g/ml amphotericin B. The explants were incubated undisturbed at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>. After 10 days of incubation, the cells were visible as outgrowth from explants. The medium was changed every three days until HGFs outgrowth reached 70-80% confluence. The cells were then harvested using trypsin (0.05%), EDTA (0.53 mM) and transferred to a 75cm<sup>2</sup> tissue culture flask. In all experiments, cells with the passage number of 3-10 were used.

### *Growth potential study*

The growth potential was studied for 120 hours on cells obtained from individuals. The cells were seeded in 24-well plates at 1 $\times$ 10<sup>4</sup> /well in triplicate. At the indicated time intervals, cells were harvested and counted using trypan blue exclusion method. The effect of various concentrations of progesterone and 17 $\beta$ -estradiol on


proliferation of these cells was studied using MTT assay. Briefly, cells were plated at 6000/well in 96-well plates and 24 hours after plating, the drugs were added to the media and incubated for 24 hours. Then, cells were incubated for 3 hours with MTT at final concentration of 0.5mg/ml. After incubation, medium was removed and the formazan crystals were dissolved in DMSO and the color was measured at 570 nm in a microplate reader.

### *Drug treatment*

The drug treatment of the HGF cells was performed as follows: PBS (as negative control or vehicle group), 10<sup>-5</sup>M 17 $\beta$ -estradiol, 10<sup>-9</sup>M 17 $\beta$ -estradiol, 10<sup>-5</sup>M progesterone, 10<sup>-9</sup>M progesterone, and a combination of 10<sup>-7</sup>M 17 $\beta$ -estradiol and 10<sup>-7</sup>M progesterone. The drug treatment was for 24 hours. Progesterone and 17 $\beta$ -estradiol were the water soluble forms specially prepared for tissue culture (Sigma-Aldrich, Germany) and were prepared in PBS at 100x stock solution.

### *Immunocytochemical procedure*

HGFs were seeded at 5 $\times$ 10<sup>4</sup> cells/well in 4-well chamber slides using DMEM, penicillin/ streptomycin (100 U/ml and 100 mg/ml, respectively) and 10% FBS, and were allowed to adhere overnight. The following day, cells were washed with PBS and rendered quiescent by culturing for 24 hours in fresh medium containing 1% FBS. After the drug treatment period, the cells were fixed with 95% ethanol: 5% acetic acid at 4°C for 5 min. The fixed cells were washed and incubated overnight at 4°C with 1% bovine serum albumin to block nonspecific binding. Following the blocking period, slides were incubated overnight at 4°C with polyclonal rabbit anti COX-2 antibody. Then, the primary antibody was washed by Tris buffer and the slides were incubated for 30 min at room temperature (RT) with 3% H<sub>2</sub>O<sub>2</sub> solution to inactivate endogenous peroxidase activity. This step was followed by incubation for 30 min at RT with biotinylated secondary antibody. COX-2 expression was visualized by addition of streptavidin-conjugated horse raddish peroxidase and diaminobenzidine tetrahydrochloride (DAB) as chromogen. Finally, slides were counterstained with hematoxylin and mounted in an aqueous mounting medium. Negative control staining consisted of the same procedure without primary antibody. After immunocytochemical staining, slides were examined under microscope and analyzed using the Olysia Bioreport software (Olympus, Japan). Digital image analysis was performed on the basis of cytoplasmic immunostaining intensity. For each chamber, at least five random fields were digitized and in each fields, DAB signal were measured in 100 cells



**Figure 1.** Growth potential of cultured human gingival fibroblasts. The cells were seeded at  $1 \times 10^4$  /ml in triplicate and counted by trypan blue exclusion method.

based on the pixel and was normalized to the background intensity (at  $\times 200$  magnification) (14, 15). The intensity of COX-2 expression obtained for each experiment was divided to the basal intensity in PBS treated group and reported as fold increase.

#### Statistical analysis

Each experiment was repeated in triplicate and the result from three independent experiments was reported as Mean  $\pm$  SEM. The results were analyzed by general linear modeling and Mean from each independent experiment was analyzed using one-way analysis of variance (ANOVA) with Tukey test as *post hoc* multiple comparisons of specific groups and  $p < 0.05$  was considered significant.

## RESULTS

#### Primary Culture of HGF cells

Primary outgrowth of cells derived from human gingival tissue samples was observed after 10 to 15 days. As examined by inverted phase-contrast microscopy, almost all the cells which grew up from the gingival tissue explants had the morphology of gingival fibroblasts. Figure 1 shows the growth potential of one of the cultured human gingival fibroblasts obtained from healthy individuals. The HGF cells, seeded at  $1 \times 10^4$ , were doubled after 36 hours and were reached to  $4 \times 10^4$  cell at 64 hours after incubation. The cells started to reach plateau phase in 120 hours after plating. The growth potential test was performed for all the HGF cells obtained from individuals. There was no difference in growth potential of HGF cells among the individuals. Furthermore, there was no significant difference in growth potential of cells obtained from either sexes (data not shown). It has been recognized that HGFs are heterogeneous *in vivo* (16), and the *in vitro* maintenance of these cells tends to reduce that heterogeneity by the


process of selection. Thus, the length of time in culture was limited to 10 passages to preserve natural heterogeneity.

#### Immunocytochemical staining of COX-2 protein

Results demonstrate that HGFs resting in growth medium containing 1% FBS, as negative controls, do not express statistically significant amounts of COX-2 protein. However, when stimulated by 17 $\beta$ -estradiol and/or progesterone, HGFs significantly express higher levels of COX-2 protein (Fig. 2 a,b,c). The COX-2 expression has been dispersed and mainly cytoplasmic. No nuclear or membrane accumulation of the protein expression was detected (Fig. 2). The result from quantitative analysis of the COX-2 expression is shown in figure 3. Compared to the negative controls, cells treated with  $10^{-5}$ M and  $10^{-9}$ M of 17 $\beta$ -estradiol, have increased COX-2 expression by 4.44 and 3.13 folds, respectively ( $P < 0.01$ , compared to no treatment). When stimulated with  $10^{-5}$ M and  $10^{-9}$ M of progesterone, the cells have expressed 5.64 and 3.53 fold increases in COX-2 expression, respectively (Fig.3,  $P < 0.01$ , compared to no treatment). These results also indicate that progesterone at  $10^{-5}$  M has a more potent effect on induction of COX-2 expression than 17 $\beta$ -estradiol at equal doses, although this effect is not significant at  $10^{-9}$ M. In HGF cells treated with a combination of  $10^{-7}$ M 17 $\beta$ -estradiol and  $10^{-7}$ M progesterone, the COX-2 expression compared to control cells increased by 5.16 fold. This result indicates that the combination of these hormones ( $10^{-7}$ M of each) has greater induction of COX-2 expression than 17 $\beta$ -estradiol at  $10^{-5}$  M but slightly smaller than progesterone at  $10^{-5}$ M. Furthermore, when the data was analyzed based on the sex of the individuals (Figure 4.), statistical analysis revealed that the induction of COX-2 expression was not sex related with neither of the hormones.

#### The effect of Progesterone and 17 $\beta$ -estradiol on growth potential of HGF cells

The effects of progesterone and 17 $\beta$ -estradiol on proliferation of HGF cells were tested (Fig. 5). The results indicated that 24 hours treatment of HGF cells with various concentrations of progesterone and 17 $\beta$ -estradiol ( $10^{-9}$ ,  $10^{-7}$ ,  $10^{-5}$ M) had no significant effect on proliferation of these cells. Treatments of cells with combination of progesterone and 17 $\beta$ -estradiol ( $10^{-9}$ ,  $10^{-7}$ ,  $10^{-5}$ M of each) had a very small inhibitory, but not significant, effect on HGF cell growth (Fig.5). The experiment was performed on cells obtained from either sex and no significant differences were observed (data not shown).



**Figure 2.** Immunocytochemically analysis of COX-2 expression in HGF cells. HGF cells with no hormonal treatment (A, negative control), stimulated by 17 $\beta$ -estradiol (B) or progesterone (C) were immunocytochemically stained for COX-2 expression.


### DISCUSSION

Using immunocytochemical staining of COX-2 protein, it was demonstrated that COX-2 is upregulated in HGFs treated by 17 $\beta$ -estradiol and progesterone (Fig.2, 3). It is well documented that COX-2 plays a pivotal role in generating high levels of proinflammatory prostaglandins locally resulting in gingival inflammation (11, 17-20). Thus, it is reasonable to suggest estradiol- and progesterone-mediated upregulation of COX-2 expression in HGFs. The HGF cells are the most abundant cells in the gingival and could contribute to the phenomenon of female sex hormone-associated gingivitis.

In recent years, in vitro cell culture assessment has been widely used to address the cellular responses to specific factors in an attempt to predict the in vivo effects of these bioactive molecules. Although fibroblasts have classically been described as engineers of the extracellular connective tissue matrix, recent investigations have markedly expanded their functions such as synthesis of various important mediators of inflammatory

processes including prostaglandins (5, 11, 20-24). It is noteworthy that the presence of both estrogen (25, 26) and progesterone receptors (22) in HGFs have been demonstrated previously, indicating that these cells possess the cellular elements necessary for response to these hormones.

In the inflammation phenomena, the role of prostaglandins (PGs) has been well characterized. Although the production of PGs is being managed by the COX-1 (constitutive) and COX-2 (inducible) forms of the COX enzyme, the role of COX-2 in inflammation has been explicit (17, 18, 27). It is known that gingival fibroblast contributes to inflammation process of gingiva by production of proinflammatory mediator including PG (11, 28, 29). It has been shown that lipopolysaccharide from periodontal pathogens, IL-1 $\beta$ , EGF, nicotin, serum and sex hormones can increase PG synthesis (5, 10, 12, 20, 23, 28, 29). Previous study on gingival homogenate has reported that progesterone and 17 $\beta$ -estradiol can induce PG formation at low concentrations ( $10^{-9}$  and  $10^{-7}$  M) but can inhibit that in higher concentrations ( $10^{-5}$  and  $10^{-3}$  M) (12), suggesting a regulatory role for female sex hormones on PG production. Furthermore, it has been demonstrated that the structure of COX-2 gene is consistent with that of an "immediate early-response" gene product which can be rapidly upregulated in response to appropriate bioactive molecules (19), such as hormones. It has been reported that COX-2 expression is increased during inflammation in gingival fibroblasts (11, 20, 21, 28-30). Moreover, progesterone and estrogen can stimulate COX-2 expression in human uterine myometrial cells (10), human uterine microvascular endothelial cells (31) and human endothelial cells (7, 8). These findings are in agreement with our in vitro findings. Which indicate an upregulation of COX-2 expression at  $10^{-9}$  and  $10^{-7}$  M of 17 $\beta$ -estradiol and progesterone (Fig. 3). Furthermore, the unstimulated HGFs is expressed at very low and statistically not significant levels of COX-2 protein, whereas stimulated HGFs are expressed at high levels of this enzyme. These data taken together with the results from tissue homogenate (12) indicates an increase in PGs and the enzyme responsible for PG production, i.e. COX-2 protein. Since HGF cells express progesterone and estrogen receptors (22, 25), the stimulation of COX-2 expression in HGF cells suggests a regulatory role for sex hormone receptors in this finding. Although we have utilized cells from either sexes, the growth potential (data not shown) as well as effect of 17 $\beta$ -estradiol and progesterone on COX-2 expression was not affected (Fig. 4). This is interesting since it could indicate the elimination of the effect of sex hormone or lack of




A, 17β-estradiol ; B, progesterone ; C, A(10<sup>-7</sup>)+B(10<sup>-7</sup>)

**Figure 3.** The COX-2 expression level in HGF cells. The cells obtained from six different individuals were treated with 17β-estradiol and progesterone with indicated concentrations. The intensity of the expression was measured as described in methods and materials and the change in expression was calculated as fold change compared to control cells (no treatment). The results are indicated as Mean ± SE of six independent cell clones (n=6) treated in triplicate.


the effects of male sex hormone on COX-2 expression. Since the cells were used after their 3<sup>rd</sup> passage, it is reasonable to consider that the sex hormone dependent gene transcription of protein has been eliminated. Thus, sex dependency of COX-2 expression has been abolished in this method. In addition, our results indicate that hormone treatment of HGF cells has no significant effect on the proliferation of these cells and proliferation has been reduced when treated with either hormones (Fig.5). These results are in agreement with Christoffers et.al findings (32) where they have found no significant effect on gingival fibroblast proliferation by sex hormones at low concentrations. However, in concentrations higher than 50 μM, progesterone inhibits the growth. Our result indicates that the effect of sex hormones on induction of COX-2 is not dependent on the proliferation of these cells.

Even though the half-life of COX-2 protein has been reported to be relatively short (33), our results show that expression of this enzyme by HGFs in response to 17β-estradiol and progesterone was elevated even after 24 hours of stimulation. These results are consistent with data in smooth muscle cells (34) and suggest that COX-2 protein may be more stable in these cell types. One advantage of immunocytochemical analysis of protein expression is to study the localization of the protein in the cell. There has been suggestions of localization of COX-2 protein to membrane upon induction or even physical interaction with p53 protein (35) in cancer cells. Our results indicate that the expression COX-2 has



A, 17β-estradiol ; B, progesterone ; C, A(10<sup>-7</sup>)+B(10<sup>-7</sup>)

**Figure 4.** The effect of sex on the COX-2 expression level in HGF cells. The cells obtained from three male and three female individuals were treated with 17β-estradiol and progesterone with indicated concentrations. The intensity of the expression was measured as described in materials and method and the change in expression was calculated as fold change compare to control cells (no treatment). The results are indicated as Mean ± SE of three independent cell clones for either sex (n=3) treated in triplicate.



**Figure 5.** The effect of Progesterone and 17β-estradiol on the growth of HGF cells. The cells were treated with either progesterone, 17β-estradiol or both at indicated concentrations for 24 hours. The growth was measured using MTT assay. The data obtained from drug treatments were normalized to control non treated cells and plotted. The results indicate Mean ± SE of eight replica (n=8). The experiment was repeated twice independently.

been disperse and mainly cytoplasmic (Fig. 3) and we could not detect any nuclear or membrane associated expression similar to our findings in BAE-1 endothelial cell (14).

**CONCLUSION**

Data obtained from this *in vitro* experiment suggest that one possible pathogenetic mechanism of the female sex hormone-associated gingivitis *in vivo* may be the synthesis of proinflammatory prostaglandins, such as prostaglandin E<sub>2</sub>, via upregulation of COX-2 expression by present in gingiva in response to elevated levels of circulating estrogens and progesterone. However, further *in vitro* and *in vivo* studies with selective COX-2 inhibitors are needed to elucidate the potential usefulness of these agents as therapeutic adjuncts in the management of female sex hormone-associated gingivitis.

**ACKNOWLEDGEMENTS**

Authors would like to express their sincere thanks to Dr. Hasani, Dr. Farhadi, and Dr. Vaezi for kindly providing the gingival tissue samples used for primary cultures.

We also would like to thank Mr. H. Akbari and Mr. A. R. Kazemi for the valuable and skillful technical assistance during every step of this study. Scientific support and useful comments of Dr. Zayeri for the statistical analysis is also gratefully acknowledged. This works has been financially supported by research grant from Deputy of Research, Tehran University of Medical Sciences to SNO and MHG.

**REFERENCES**

1. Machtei EE, Mahler D, Sanduri H, Peled M. The effect of menstrual cycle on periodontal health. *J Periodontol* 2004;75(3):408-12.
2. Zachariassen RD. The effect of elevated ovarian hormones on periodontal health: oral contraceptives and pregnancy. *Women Health* 1993;20(2):21-30.
3. Soory M. Hormonal factors in periodontal disease. *Dent Update* 2000;27(8):380-3.
4. Zachariassen RD. Ovarian hormones and gingivitis. *J Dent Hyg* 1991;65(3):146-50.
5. Sooriyamoorthy M, Gower DB. Hormonal influences on gingival tissue: relationship to periodontal disease. *J Clin Periodontol* 1989;16(4):201-8.
6. Goodson JM, Dewhirst FE, Brunetti A. Prostaglandin E<sub>2</sub> levels and human periodontal disease. *Prostaglandins* 1974;6(1):81-5.
7. Hermenegildo C, Oviedo PJ, Cano A. Cyclooxygenases regulation by estradiol on endothelium. *Curr Pharm Des* 2006;12(2):205-15.
8. Selles J, Polini N, Alvarez C, Massheimer V. Novel action of estrone on vascular tissue: regulation of NOS and COX activity. *Steroids* 2005;70(4):251-6.
9. Razmara A, Krause DN, Duckles SP. Testosterone augments endotoxin-mediated cerebrovascular inflammation in male rats. *Am J Physiol Heart Circ Physiol* 2005;289(5):H1843-50.
10. Korita D, Itoh H, Sagawa N, Yura S, Yoshida M, Kakui K, Takemura M, Fujii S. 17beta-estradiol up-regulates prostacyclin production in cultured human uterine myometrial cells via augmentation of both cyclooxygenase-1 and prostacyclin synthase expression. *J Soc Gynecol Investig* 2004;11(7):457-64.
11. Morton RS, Dongari-Bagtzoglou AI. Cyclooxygenase-2 is upregulated in inflamed gingival tissues. *J Periodontol* 2001;72(4):461-9.
12. ElAttar TM, Lin HS, Tira DE. The relationship between the concentration of female sex steroids and prostaglandins production by human gingiva *in vitro*. *Prostaglandins Leukot Med* 1982;8(5):447-58.
13. Somerman MJ, Archer SY, Imm GR, Foster RA. A comparative study of human periodontal ligament cells and gingival fibroblasts *in vitro*. *J Dent Res* 1988;67(1):66-70.
14. Ostad SN, Amini M, Haghypour Z, Karimi L, Navidpour L, Ghahremani MH, Shafiee A. Inhibitory activities of new series of 4,5-diaryl thiadiazoles derivatives on lipopolysaccharide-induced Cox-2 expression. *Int J Pharmacol* 2005;1(1):79-84.
15. Choi HB, Khoo C, Ryu JK, van Breemen E, Kim SU, McLarnon JG. Inhibition of lipopolysaccharide-induced cyclooxygenase-2, tumor necrosis factor-alpha and [Ca<sup>2+</sup>]<sub>i</sub> responses in human microglia by the peripheral benzodiazepine receptor ligand PK11195. *J Neurochem* 2002;83:546-555.
16. Fries KM, Blieden T, Looney RJ, Sempowski GD, Silvera MR, Willis RA, Phipps RP. Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. *Clin Immunol Immunopathol* 1994;72(3):283-92.
17. Patrignani P, Tacconelli S, Sciuilli MG, Capone ML. New insights into COX-2 biology and inhibition. *Brain Res Brain Res Rev* 2005;48(2):352-9.
18. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. *Pharmacol Rev* 2004;56(3):387-437.
19. Simon LS. Role and regulation of cyclooxygenase-2 during inflammation. *Am J Med* 1999;106(5B):37S-42S.

20. Yucel-Lindberg T, Ahola H, Carlstedt-Duke J, Modeer T. Involvement of tyrosine kinases on cyclooxygenase expression and prostaglandin E2 production in human gingival fibroblasts stimulated with interleukin-1beta and epidermal growth factor. *Biochem Biophys Res Commun* 1999;257(2):528-32.
21. Huang FM, Chang YC. Induction of cyclooxygenase-2 mRNA and protein expression by dentin bonding agents in human gingival fibroblasts. *J Biomed Mater Res* 2004;70B(2):297-302.
22. Kawahara K, Shimazu A. Expression and intracellular localization of progesterone receptors in cultured human gingival fibroblasts. *J Periodontal Res* 2003;38(3):242-6.
23. Lapp CA, Lapp DF. Analysis of interleukin-activated human gingival fibroblasts: modulation of chemokine responses by female hormones. *J Periodontol* 2005;76(5):803-12.
24. Tilakaratne A, Soory M. Modulation of androgen metabolism by estradiol-17beta and progesterone, alone and in combination, in human gingival fibroblasts in culture. *J Periodontol* 1999;70(9):1017-25.
25. Parkar MH, Newman HN, Olsen I. Polymerase chain reaction analysis of oestrogen and androgen receptor expression in human gingival and periodontal tissue. *Arch Oral Biol* 1996;41(10):979-83.
26. Vittek J, Hernandez MR, Wenk EJ, Rappaport SC, Southren AL. Specific estrogen receptors in human gingiva. *J Clin Endocrinol Metab* 1982;54(3):608-12.
27. Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. *J Clin Invest* 2001;107(12):1491-5.
28. Chang YC, Tsai CH, Yang SH, Liu CM, Chou MY. Induction of cyclooxygenase-2 mRNA and protein expression in human gingival fibroblasts stimulated with nicotine. *J Periodontal Res* 2003;38(5):496-501.
29. Sakurai Y, Yamaguchi M, Abiko Y. Inhibitory effect of low-level laser irradiation on LPS-stimulated prostaglandin E2 production and cyclooxygenase-2 in human gingival fibroblasts. *Eur J Oral Sci* 2000;108(1):29-34.
30. Lohinai Z, Stachlewitz R, Szekely AD, Feher E, Dezsi L, Szabo C. Evidence for the expression of cyclooxygenase-2 enzyme in periodontitis. *Life Sci* 2001;70(3):279-90.
31. Tamura M, Deb S, Sebastian S, Okamura K, Bulun SE. Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. *Fertil Steril* 2004;81(5):1351-6.
32. Christoffers AB, Kreisler M, Willershausen B. Effects of estradiol and progesterone on the proliferation of human gingival fibroblasts. *Eur J Med Res* 2003;8(12):535-42.
33. O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. *Proc Natl Acad Sci U S A* 1992;89(11):4888-92.
34. Pritchard KA, Jr., O'Banion MK, Miano JM, Vlastic N, Bhatia UG, Young DA, Stemerman MB. Induction of cyclooxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo. *J Biol Chem* 1994;269(11):8504-9.
35. Corcoran CA, He Q, Huang Y, Sheikh MS. Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis. *Oncogene* 2005;24(9):1634-40.